WO2019172740A1 - Formulation for solidifying blood of animal origin - Google Patents

Formulation for solidifying blood of animal origin Download PDF

Info

Publication number
WO2019172740A1
WO2019172740A1 PCT/MX2018/000035 MX2018000035W WO2019172740A1 WO 2019172740 A1 WO2019172740 A1 WO 2019172740A1 MX 2018000035 W MX2018000035 W MX 2018000035W WO 2019172740 A1 WO2019172740 A1 WO 2019172740A1
Authority
WO
WIPO (PCT)
Prior art keywords
blood
formulation
animal origin
further characterized
origin according
Prior art date
Application number
PCT/MX2018/000035
Other languages
Spanish (es)
French (fr)
Inventor
Gerardo Alonso Torres Ávalos
Edith Ariadna LOZANO GONZÁLEZ
María Rebeca ENRÍQUEZ GUTIÉRREZ
Claudia Alejandra MACÍAS CHÁVEZ
Original Assignee
Instituto Tecnológico José Mario Molina Pasquel y Henriquez
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Instituto Tecnológico José Mario Molina Pasquel y Henriquez filed Critical Instituto Tecnológico José Mario Molina Pasquel y Henriquez
Publication of WO2019172740A1 publication Critical patent/WO2019172740A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/20—Animal feeding-stuffs from material of animal origin
    • A23K10/24—Animal feeding-stuffs from material of animal origin from blood

Definitions

  • the present invention is related to formulations for treating blood of animal origin, and more specifically is related to formulations for solidifying blood of animal origin.
  • animal blood can have various uses, such as protein source, to produce reagents for diagnosis and biotechnology or even to make cosmetics.
  • the main use of animal blood is as a source of protein.
  • Dried plasma can be given as feed to livestock animals or pets.
  • the procedures for treating animal blood are usually very complicated.
  • Products have also been developed to promote blood coagulation such as the prothrombin complex, fresh frozen plasma and precipitated cryo.
  • Another product that is commonly used is the recombinant human vile factor, which is used to treat major hemorrhages.
  • the tranexámlco and the aminocapróddo adduce inhibit fibrinólisls, and lead to a dlsminudón in the rate of bleeding.
  • Aprotinlna was also widely used in arugias to reduce bleeding bleeding and the need for blood products.
  • the present invention seeks to develop a liquid blood treatment method resulting from the processing of trace animals so that it can be used in the fed industry by applying similar ingredients to those used in the pharmaceutical industry.
  • the present invention solves all the problems and disadvantages identified in the background of the invention.
  • a first aspect of the present invention is a formulation for solidifying blood of animal origin comprising at least one gelling agent; a coagulation accelerating agent; and an edible vehicle.
  • a second aspect of the present invention is a method for obtaining a formulation for solidifying blood of animal origin comprising heating an edible vehicle; and add a gelling agent and a coagulation accelerator agent to the edible suspension medium until a homogeneous solder is obtained.
  • a third aspect of the present invention is a method for solidifying blood of animal origin that comprises maintaining a formulation to solidify blood of animal origin at a temperature between 50 and 70 ° C; add blood of animal origin in a liquid state to the formulation; shake the solderon until solid particles of blood are obtained; and separating said particles from the soludón.
  • a final aspect of the present invention is solid blood of animal origin, obtained by the method to solidify blood of animal origin of the present invention, with a density of between 1,080 and 1.12 g / mL, an average modulus of elasticity between 40 and 133 KPa, and a deviation from the mean square value (RMS) between 1.2 and 2.35 KPa.
  • RMS mean square value
  • a first aspect of the present invention is a formulation for solidifying blood of animal origin comprising at least one gelling agent; a coagulation accelerating agent; and an edible vehicle.
  • the gelling agent of the formulation is selected from among grenetina, guar gum and combinations thereof. Even more preferably, it is a combination of grenetina and guar gum.
  • the gelling agent of the formulation is in a concentration of between 1.5 and 14% by weight. Even more preferably in a concentration of 10% by weight.
  • the coagulation accelerating agent is broth chloride. In a preferred embodiment of the present invention, the coagulation accelerating agent is in a concentration of between 1 and 5% by weight. Even more preferably it is in a concentration of 1.4% by weight.
  • the edible carrier is selected from the groups of alcohols, diols, thiols, and combinations thereof.
  • it is selected from gllcerin, propylene glycol, ethanol, and combinations thereof.
  • the edible vehicle is in a concentration between 9.6 and 27% by weight. In an even more preferred embodiment it is in a concentration of 17% by weight.
  • the formulation additionally contains a preservative that does not intervene with the solidification reactions of the blood.
  • the preservative is selected from sodium benzoate and sodium propionate.
  • the preservative is in a concentration of between 0.05 and 0.1% by weight. Even more preferably, it is in a concentration of 0.1% by weight.
  • a second aspect of the present invention is a method of obtaining a formulation for solidifying blood of animal origin comprising heating an edible vehicle; and add a gelling agent and a coagulation accelerating agent to the edible suspension medium until a homogeneous solution is obtained.
  • the addition of the gelling agent and coagulation accelerating agent can be carried out simultaneously or by adding one after the other.
  • the edible vehicle is selected from the groups of alcohols, diols, thiols, and combinations thereof.
  • it is selected from glycerin, propylene glycol, ethanol, and combinations thereof.
  • the amount of edible vehicle that falls within the first stage of the method of the present invention is such that the final formulation contains a concentration of between 9.6 and 27% by weight of said edible vehicle.
  • the amount is such that the concentration is 10% by weight.
  • the edible vehicle is heated to a temperature between 50 and 70 ° C. Even more preferably it is at a temperature of 60 ° C.
  • the gelling agent is selected from grenetine, guar gum, and combinations thereof. Even more preferred is a combination of grenetina and guar gum.
  • the amount of gelling agent that is added to the edible carrier is such that the final formulation contains a concentration of gelling agent of between 1.5 and 20% by weight mL.
  • the amount is such that the concentration is 10% by weight.
  • the coaguladon accelerating agent is calcium chloride.
  • the amount of coagulation accelerating agent that is added to the edible vehicle is such that the final formulation contains a coagulation accelerating agent concentration of between 1 and 5% by weight.
  • the amount is such that the concentration is 1.4% by weight.
  • the gelling agent and the coagulation accelerating agent are added gradually with constant agitation.
  • the method opdonally comprises an additional step in which a preservative that does not intervene with the solidification reactions of the blood is added.
  • the preservative is selected from sodium benzoate and sodium propionate.
  • the preservative is added in an amount such that the concentration of said preservative in the final formulation is between 0.05 and 0.1% by weight.
  • it is added in an amount such that the concentration of said preservative in the final formulation is 0.1% by weight.
  • the strengthening of the mechanical properties of the solidified blood is achieved by the joint action of calcium chloride and the gelling agent (s).
  • the calcium ions present in the formulation promote blood coagulation while the gelling agent (s) dramatically decrease the mobility of semi-solid and particulate elements, such as cells and components derived from cells that constitute about 45% of the blood. Thanks to the synergistic acdon of these agents, it is possible to accelerate blood coagulation and thus obtain solid blood particles.
  • a third aspect of the present invention is a method for solidifying blood of animal origin comprising maintaining a formulation to solidify blood of animal origin at a temperature between 50 and 70 ° C; add blood of animal origin in liquid form to the formulation; stir the solution until solid particles of blood are obtained; and separating said particles from the solution.
  • the formulation for solidifying blood of animal origin is maintained at a temperature of 60 ° C.
  • the animal blood of the present invention can be directly extracted from the animal or it can come from some other procedure. However, it is necessary that said blood be in a liquid state.
  • Any known solid-liquid separation method can be used to separate the particles from the solution.
  • the method of solidification of the blood previously described achieves the strengthening of the mechanical properties of animal blood by forming a three-dimensional structure by acdon of the gelling agent and reinforcing said network by the formulation of the broth ions.
  • a final aspect of the present invention is solid blood of animal origin, obtained by the method to solidify blood of animal origin of the present invention, with a density of between 1,080 and 1.12 g / mL, an average modulus of elasticity between 40 and 133 KPa, and an average square value (RMS) between 1.2 and 2.35 KPa.
  • the density of the solid blood obtained is between 1,082 and 1,115 g / mL.
  • 1,111 g / mL Preferably, 1,111 g / mL.
  • the average elastic modulus of solid blood obtained is 56.6 KPa.
  • the mean quadratic value (RMS) of the solid blood obtained is 1.8 KPa.
  • formulation to solidify blood of animal origin has been devised to carry out solidification of blood of animal origin with efficiency, and it will be apparent to any person skilled in the art that the modalities of the formulation to solidify blood of animal origin as described above, they are only illustrative but not limiting of the present invention, since numerous changes of consideration in their details are possible without departing from the scope of the Invention.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Animal Husbandry (AREA)
  • Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention describes: a formulation for solidifying blood of animal origin by means of a gelling agent, a clotting accelerator and an edible vehicle; a method for obtaining a formulation for solidifying blood of animal origin; a method for solidifying blood of animal origin; and the solid blood of animal origin.

Description

FORMULACIÓN PARA SOLIDIFICAR SANGRE DE ORIGEN ANIMAL  FORMULATION TO SOLIDIFY BLOOD OF ANIMAL ORIGIN
CAMPO DE LA INVENCIÓN FIELD OF THE INVENTION
La presente Invención está reladonada con formulaciones para tratar sangre de origen animal, y más específicamente está relacionada con las formulaciones para solidificar sangre de origen animal.  The present invention is related to formulations for treating blood of animal origin, and more specifically is related to formulations for solidifying blood of animal origin.
ANTECEDENTES DE LA INVENCIÓN BACKGROUND OF THE INVENTION
En México existen 678 rastros registrados donde se realizan sacrificios de bovinos y porcinos. A partir de la gran cantidad de animales sacrificados, se genera una gran cantidad de aguas residuales. Esto representa un gran problema ambiental ya que dicha agua tiende a verterse en cuerpos de agua, al alcantarillado o al campo abierto. 0 principal contaminante generado en los rastros es la sangre, que aporta un DQO aproximado de 370,000 mg/L  In Mexico there are 678 registered trails where cattle and pig slaughter are made. From the large number of animals slaughtered, a large amount of wastewater is generated. This represents a major environmental problem since such water tends to pour into bodies of water, sewer or open field. 0 main contaminant generated in the traces is the blood, which provides an approximate COD of 370,000 mg / L
SI es adecuadamente tratada, la sangre animal puede tener diversos usos, tales como fuente de proteínas, para producir reactivos para diagnóstico y biotecnología o incluso para fabricar cosméticos. 0 principal uso de la sangre animal es como fuente de proteínas. 0 plasma desecado se puede dar como alimento a animales de ganado o a mascotas. Sin embargo, los procedimientos para tratar la sangre animal suelen ser muy complicados.  If properly treated, animal blood can have various uses, such as protein source, to produce reagents for diagnosis and biotechnology or even to make cosmetics. The main use of animal blood is as a source of protein. Dried plasma can be given as feed to livestock animals or pets. However, the procedures for treating animal blood are usually very complicated.
Por otro lado, se han desarrollado diversos procedimientos en el área de la salud para favorecer la coagulación de la sangre y el sellado de las heridas. Algunos de dichos procedimientos emplean productos absorbentes tales como zeolltas y otros agentes hemostáticos para lograrlo.  On the other hand, various procedures have been developed in the area of health to promote blood clotting and wound sealing. Some of these procedures employ absorbent products such as zeolltas and other hemostatic agents to achieve this.
También se han desarrollado productos para promover la coagulación sanguínea tales como el complejo de protrombina, plasma fresco congelado y crio precipitado. Otro producto que se emplea comúnmente es el factor vil humano recombinante, mismo que se emplea para tratar hemorragias mayores. También, el áddo tranexámlco y el áddo aminocapróico Inhiben la fibrinólisls, y conducen a una dlsminudón en la tasa de sangrado. La aprotinlna también se empleaba mucho en las arugías para disminuir el resigo de sangrado y la necesidad de derivados sanguíneos.  Products have also been developed to promote blood coagulation such as the prothrombin complex, fresh frozen plasma and precipitated cryo. Another product that is commonly used is the recombinant human vile factor, which is used to treat major hemorrhages. Also, the tranexámlco and the aminocapróddo adduce inhibit fibrinólisls, and lead to a dlsminudón in the rate of bleeding. Aprotinlna was also widely used in arugias to reduce bleeding bleeding and the need for blood products.
Aunque las tecnologías mendonadas tienen la capaddad de favorecer la coaguladón de la sangre, éstas están enfocadas en el tratamiento de heridas de seres humanos o de animales, y no en el tratamiento de la sangre residual de un rastro. La presente Invendón busca desarrollar un método de tratamiento de sangre líquida resultante del procesamiento de animales de rastro para que se pueda emplear en la Industria alimentada aplicando prindpios similares a los empleados en la Industria farmacéutica.  Although beggaring technologies have the ability to favor blood clotting, they are focused on the treatment of wounds of humans or animals, and not on the treatment of residual blood from a trail. The present invention seeks to develop a liquid blood treatment method resulting from the processing of trace animals so that it can be used in the fed industry by applying similar ingredients to those used in the pharmaceutical industry.
OBJETOS DE LA INVENCIÓN OBJECTS OF THE INVENTION
considerando los problemas y desventajas del estado de la técnica que se mencionó previamente, es un objeto de la presente invendón proporcionar un BREVE DESCRIPCIÓN DE LA INVENCIÓN. Considering the problems and disadvantages of the prior art mentioned above, it is an object of the present invention to provide a BRIEF DESCRIPTION OF THE INVENTION.
La presente invención resuelve todos los problemas y desventajas identificados en los antecedentes de la Invención.  The present invention solves all the problems and disadvantages identified in the background of the invention.
Un primer aspecto de la presente Invención es una formulación para solidificar sangre de origen animal que comprende al menos un agente gelificante; un agente acelerador de la coagulación; y un vehículo comestible.  A first aspect of the present invention is a formulation for solidifying blood of animal origin comprising at least one gelling agent; a coagulation accelerating agent; and an edible vehicle.
Un segundo aspecto de la presente Invendón es un método para obtener una formulatión para solidificar sangre de origen animal que comprende calentar un vehículo comestible; y añadir un agente gelificante y un agente acelerador de la coagulatión al medio de suspensión comestible hasta obtener una soludón homogénea.  A second aspect of the present invention is a method for obtaining a formulation for solidifying blood of animal origin comprising heating an edible vehicle; and add a gelling agent and a coagulation accelerator agent to the edible suspension medium until a homogeneous solder is obtained.
Un tercer aspecto de la presente invendón es un método para solidificar sangre de origen animal que comprende mantener una formuladón para solidificar sangre de origen animal a una temperatura de entre 50 y 70°C; añadir sangre de origen animal en estado líquido a la formuladón; agitar la soludón hasta obtener partículas sólidas de sangre; y separar dichas partículas de la soludón.  A third aspect of the present invention is a method for solidifying blood of animal origin that comprises maintaining a formulation to solidify blood of animal origin at a temperature between 50 and 70 ° C; add blood of animal origin in a liquid state to the formulation; shake the solderon until solid particles of blood are obtained; and separating said particles from the soludón.
Un último aspecto de la presente Invendón es sangre sólida de origen animal, obtenida por el método para solidificar sangre de origen animal de la presente Invendón, con una densidad de entre 1.080 y 1.12 g/mL ,un módulo de elastiddad promedio de entre 40 y 133 KPa, y una desviadón del valor cuadrático medio (RMS) de entre 1.2 y 2.35 KPa.  A final aspect of the present invention is solid blood of animal origin, obtained by the method to solidify blood of animal origin of the present invention, with a density of between 1,080 and 1.12 g / mL, an average modulus of elasticity between 40 and 133 KPa, and a deviation from the mean square value (RMS) between 1.2 and 2.35 KPa.
DESCRIPCIÓN DETALLADA DE LA INVENCIÓN DETAILED DESCRIPTION OF THE INVENTION
Como se mencionó en los antecedentes, el principal contaminante originado en los rastros es la sangre, misma que presenta un riesgo ambiental ya que puede contaminar tanto agua como tierra. El tratamiento de este residuo es muy complicado y su manejo requiere mucho cuidado. Para resolver este problema, se ha encontrado que se puede aplicar tecnología farmacéutica relativa a la coagulación de la sangre humana para lograr solidificar la sangre animal y así facilitar su manejo y favorecer su aprovechamiento como alimento animal.  As mentioned in the background, the main contaminant originated in the trails is blood, which presents an environmental risk since it can contaminate both water and soil. The treatment of this residue is very complicated and its handling requires a lot of care. To solve this problem, it has been found that pharmaceutical technology related to the coagulation of human blood can be applied to solidify animal blood and thus facilitate its handling and favor its use as animal food.
De acuerdo con lo anterior, un primer aspecto de la presente Invención es una formulación para solidificar sangre de origen animal que comprende al menos un agente gelificante; un agente acelerador de la coagulación; y un vehículo comestible.  In accordance with the foregoing, a first aspect of the present invention is a formulation for solidifying blood of animal origin comprising at least one gelling agent; a coagulation accelerating agent; and an edible vehicle.
En una modalidad preferida de la presente invención, el agente gelificante de la formulación es seleccionado de entre grenetina, goma guar y combinaciones de los mismos. De manera aún más preferida, es una combinación de grenetina y goma guar.  In a preferred embodiment of the present invention, the gelling agent of the formulation is selected from among grenetina, guar gum and combinations thereof. Even more preferably, it is a combination of grenetina and guar gum.
En una modalidad preferida de la presente Invención, el agente gelificante de la formulación está en una concentración de entre 1.5 y 14 % en peso. De manera aún más preferida en una concentración de 10% en peso.  In a preferred embodiment of the present invention, the gelling agent of the formulation is in a concentration of between 1.5 and 14% by weight. Even more preferably in a concentration of 10% by weight.
En una modalidad preferida de la presente Invención, el agente acelerador de la coagulación es cloruro de caldo. En una modalidad preferida de la presente invención, el agente acelerador de la coagulación está en una concentración de entre 1 y 5 % en peso. De manera aún más preferida está en una concentración de 1.4% en peso. In a preferred embodiment of the present invention, the coagulation accelerating agent is broth chloride. In a preferred embodiment of the present invention, the coagulation accelerating agent is in a concentration of between 1 and 5% by weight. Even more preferably it is in a concentration of 1.4% by weight.
En una modalidad preferida de la presente invención, el vehículo comestible se selecciona de entre los grupos de alcoholes, dioles, tioles, y combinaciones de los mismos. Preferiblemente sé selecciona de entre gllcerina, propilengllcol, etanol, y combinaciones de los mismos.  In a preferred embodiment of the present invention, the edible carrier is selected from the groups of alcohols, diols, thiols, and combinations thereof. Preferably, it is selected from gllcerin, propylene glycol, ethanol, and combinations thereof.
En una modalidad preferida, el vehículo comestible está en una concentración de entre 9.6 y 27 % en peso. En una modalidad aún más preferida está en una concentración de 17% en peso.  In a preferred embodiment, the edible vehicle is in a concentration between 9.6 and 27% by weight. In an even more preferred embodiment it is in a concentration of 17% by weight.
En una modalidad opcional de la presente Invención, la formulación contiene adicionalmente un conservador que no Interviene con las reacciones de solidificación de la sangre. Preferiblemente, el conservador se selecciona de entre benzoato de sodio y propionato de sodio. Preferiblemente, el conservador está en una concentración de entre 0.05 y 0.1% en peso. De manera aún más preferida, está en una concentración de 0.1 % en peso.  In an optional embodiment of the present invention, the formulation additionally contains a preservative that does not intervene with the solidification reactions of the blood. Preferably, the preservative is selected from sodium benzoate and sodium propionate. Preferably, the preservative is in a concentration of between 0.05 and 0.1% by weight. Even more preferably, it is in a concentration of 0.1% by weight.
Adicionalmente, un segundo aspecto de la presente Invención es un método para obtener una formulación para solidificar sangre de origen animal que comprende calentar un vehículo comestible; y añadir un agente gelificante y un agente acelerador de la coagulación al medio de suspensión comestible hasta obtener una solución homogénea.  Additionally, a second aspect of the present invention is a method of obtaining a formulation for solidifying blood of animal origin comprising heating an edible vehicle; and add a gelling agent and a coagulation accelerating agent to the edible suspension medium until a homogeneous solution is obtained.
La adición del agente gelificante y agente acelerador de la coagulación puede llevarse a cabo de manera simultánea o añadiendo uno después del otro.  The addition of the gelling agent and coagulation accelerating agent can be carried out simultaneously or by adding one after the other.
En una modalidad preferida de la presente Invención, el vehículo comestible se selecciona de entre los grupos de alcoholes, dioles, tioles, y combinaciones de los mismos. Preferiblemente se selecciona de entre glicerina, propilengllcol, etanol, y combinaciones de los mismos.  In a preferred embodiment of the present invention, the edible vehicle is selected from the groups of alcohols, diols, thiols, and combinations thereof. Preferably it is selected from glycerin, propylene glycol, ethanol, and combinations thereof.
La cantidad de vehículo comestible que se callenta en la primera etapa del método de la presente Invención es tal que la formulación final contiene una concentración de entre 9.6 y 27 % en peso de dicho vehículo comestible. Preferiblemente, la cantidad es tal que la concentración es de 10% en peso.  The amount of edible vehicle that falls within the first stage of the method of the present invention is such that the final formulation contains a concentration of between 9.6 and 27% by weight of said edible vehicle. Preferably, the amount is such that the concentration is 10% by weight.
En una modalidad preferida de la presente Invención, el vehículo comestible se calienta a una temperatura de entre 50 y 70°C. De manera aún más preferible se callenta a una temperatura de 60°C.  In a preferred embodiment of the present invention, the edible vehicle is heated to a temperature between 50 and 70 ° C. Even more preferably it is at a temperature of 60 ° C.
En una modalidad preferida de la presente Invención, el agente gelificante es seleccionado de entre grenetina, goma guar, y combinaciones de los mismos. De manera aún más preferida es una combinación de grenetina y goma guar.  In a preferred embodiment of the present invention, the gelling agent is selected from grenetine, guar gum, and combinations thereof. Even more preferred is a combination of grenetina and guar gum.
La cantidad de agente gelificante que se añade al vehículo comestible es tal que la formulación final contiene una concentración de agente gelificante de entre 1.5 y 20 % en peso mL Preferiblemente, la cantidad es tal que la concentración es de 10% en peso.  The amount of gelling agent that is added to the edible carrier is such that the final formulation contains a concentration of gelling agent of between 1.5 and 20% by weight mL. Preferably, the amount is such that the concentration is 10% by weight.
En una modalidad preferida de la presente invención, el agente acelerador de la coaguladón es cloruro de calcio. La cantidad de agente acelerador de la coagulación que se añade al vehículo comestible es tal que la formulación final contiene una concentración de agente acelerador de la coagulación de entre 1 y 5 % en peso. Preferiblemente, la cantidad es tal que la concentración es de 1.4% en peso. In a preferred embodiment of the present invention, the coaguladon accelerating agent is calcium chloride. The amount of coagulation accelerating agent that is added to the edible vehicle is such that the final formulation contains a coagulation accelerating agent concentration of between 1 and 5% by weight. Preferably, the amount is such that the concentration is 1.4% by weight.
En una modalidad preferida de la presente invención, el agente gelificante y el agente acelerador de la coagulación se añaden de manera paulatina con agitación constante.  In a preferred embodiment of the present invention, the gelling agent and the coagulation accelerating agent are added gradually with constant agitation.
En una modalidad preferida de la presente invención, el método comprende opdonalmente una etapa adicional en la que se agrega un conservador que no intervenga con las reacciones de solidificación de la sangre. Preferiblemente, el conservador se selecciona de entre benzoato de sodio y propionato de sodio. Preferiblemente el conservador se agrega en una cantidad tal que la concentración de dicho conservada- en la formulación final es de entre 0.05 y 0.1 % en peso. Preferiblemente, se agrega en una cantidad tal que la concentración de dicho conservador en la formulación final es de 0.1 % en peso.  In a preferred embodiment of the present invention, the method opdonally comprises an additional step in which a preservative that does not intervene with the solidification reactions of the blood is added. Preferably, the preservative is selected from sodium benzoate and sodium propionate. Preferably the preservative is added in an amount such that the concentration of said preservative in the final formulation is between 0.05 and 0.1% by weight. Preferably, it is added in an amount such that the concentration of said preservative in the final formulation is 0.1% by weight.
Empleando la formulación para solidificar sangre de origen animal, se logra el reforzamiento de las propiedades mecánicas de la sangre solidificada por la acción conjunta del cloruro de calcio y el o los agentes gelificantes. Los iones de calcio presentes en la formulación promueven la coagulación sanguínea mientras que el o los agentes gelificantes disminuyen drásticamente la movilidad de los elementos semisólidos y particulados, tales como células y componentes derivados de las células que constituyen alrededor del 45% de la sangre. Gracias a la acdón sinérgica de dichos agentes, se logra acelerar la coagulación de la sangre y así, obtener partículas de sangre sólida.  Using the formulation to solidify blood of animal origin, the strengthening of the mechanical properties of the solidified blood is achieved by the joint action of calcium chloride and the gelling agent (s). The calcium ions present in the formulation promote blood coagulation while the gelling agent (s) dramatically decrease the mobility of semi-solid and particulate elements, such as cells and components derived from cells that constitute about 45% of the blood. Thanks to the synergistic acdon of these agents, it is possible to accelerate blood coagulation and thus obtain solid blood particles.
Así, un tercer aspecto de la presente Invención es un método para solidificar sangre de origen animal que comprende mantener una formulación para solidificar sangre de origen animal a una temperatura de entre 50 y 70°C; añadir sangre de origen animal en estado líquido a la formulación; agitar la solución hasta obtener partículas sólidas de sangre; y separar dichas partículas de la solución.  Thus, a third aspect of the present invention is a method for solidifying blood of animal origin comprising maintaining a formulation to solidify blood of animal origin at a temperature between 50 and 70 ° C; add blood of animal origin in liquid form to the formulation; stir the solution until solid particles of blood are obtained; and separating said particles from the solution.
En una modalidad preferida de la presente Invención, la formulación para solidificar sangre de origen animal se mantiene a una temperatura de 60°C.  In a preferred embodiment of the present invention, the formulation for solidifying blood of animal origin is maintained at a temperature of 60 ° C.
La sangre animal de la presente invención puede ser directamente extraída del animal o puede venir de algún otro procedimiento. Sin embargo, es necesario que dicha sangre esté en estado líquido.  The animal blood of the present invention can be directly extracted from the animal or it can come from some other procedure. However, it is necessary that said blood be in a liquid state.
Para separar las partículas de la solución se puede emplear cualquier método físico de separación sólido-líquido conocido.  Any known solid-liquid separation method can be used to separate the particles from the solution.
El método de solidificación de la sangre previamente descrito logra el reforzamiento de las propiedades mecánicas de la sangre animal al formar una estructura tridimensional por acdón del agente gelificante y reforzar dicha red por la estlmuladón de los iones de caldo. Estos efectos logran que la sangre obtenida tenga una mejor resistenda mecánica y propiedades adecuadas para facilitar su transporte y posterior aprovechamiento en otras Industrias.  The method of solidification of the blood previously described achieves the strengthening of the mechanical properties of animal blood by forming a three-dimensional structure by acdon of the gelling agent and reinforcing said network by the formulation of the broth ions. These effects ensure that the blood obtained has a better mechanical resistance and adequate properties to facilitate its transport and subsequent use in other industries.
Por lo anterior, un último aspecto de la presente invendón es sangre sólida de origen animal, obtenida por el método para solidificar sangre de origen animal de la presente Invendón, con una densidad de entre 1.080 y 1.12 g/mL, un módulo de elastiddad promedio de entre 40 y 133 KPa, y un valor cuadrático medio (RMS) de entre 1.2 y 2.35 KPa. En una modalidad preferida de la presente invención, la densidad de la sangre sólida obtenida es de entre 1.082 y 1.115 g/mL Preferiblemente, de 1.11 g/mL Therefore, a final aspect of the present invention is solid blood of animal origin, obtained by the method to solidify blood of animal origin of the present invention, with a density of between 1,080 and 1.12 g / mL, an average modulus of elasticity between 40 and 133 KPa, and an average square value (RMS) between 1.2 and 2.35 KPa. In a preferred embodiment of the present invention, the density of the solid blood obtained is between 1,082 and 1,115 g / mL. Preferably, 1,111 g / mL.
En una modalidad preferida de la presente invención, el módulo de elasticidad promedio de la sangre sólida obtenida es de 56.6 KPa.  In a preferred embodiment of the present invention, the average elastic modulus of solid blood obtained is 56.6 KPa.
En una modalidad preferida de la presente Invención, el valor cuadrática medio (RMS) de la sangre sólida obtenida es de 1.8 KPa.  In a preferred embodiment of the present invention, the mean quadratic value (RMS) of the solid blood obtained is 1.8 KPa.
La presente Invención será mejor entendida a partir de los siguientes ejemplos, los cuales se presentan únicamente con fines ilustrativos para permitir la comprensión cabal de las modalidades preferidas de la presente invención, sin que por ello se implique que no existen otras modalidades no Ilustradas que puedan llevarse a la práctica con base en la descripción detallada arriba realizada.  The present invention will be better understood from the following examples, which are presented for illustrative purposes only to allow full understanding of the preferred modalities of the present invention, without implying that there are no other non-Illustrated modalities that may be implemented based on the detailed description above.
EJEMPLO 1 EXAMPLE 1
Se llevó a cabo un ensayo para estudiar la solidificación de sangre animal empleando la formulación de la presente invención así como el procedimiento de solidificación descrito. Para este ensayo, se tomaron 30 L de glicerol al cual se le añadieron 5 Kg de goma guar, 5 Kg de grenetina y 1 Kg de cloruro de calcio. Se elevó la temperatura de la mezcla a alrededor de 60 °C y se añadieron lentamente 100 Kg de sangre animal manteniendo una agitación constante hasta que se observó la solidificación de la misma. Posteriormente, se recuperó la sangre solidificada y se analizó bajo la norma ASTM D3574 en una máquina de ensayos marca Instron modelo 3369.  An assay was carried out to study the solidification of animal blood using the formulation of the present invention as well as the solidification process described. For this test, 30 L of glycerol were taken to which 5 kg of guar gum, 5 kg of grenetine and 1 kg of calcium chloride were added. The temperature of the mixture was raised to about 60 ° C and 100 kg of animal blood was added slowly maintaining constant stirring until solidification was observed. Subsequently, solidified blood was recovered and analyzed under ASTM D3574 in an Instron model 3369 test machine.
A partir de los análisis realizados, se detectó que la sangre obtenida presentó las siguientes características:  From the analyzes performed, it was detected that the blood obtained had the following characteristics:
Módulo de elasticidad promedio: 56.6 KPa  Average modulus of elasticity: 56.6 KPa
RMS: 1.8 KPa  RMS: 1.8 KPa
Densidad: 1.082-1.115 g/mL  Density: 1,082-1,115 g / mL
De conformidad con lo anteriormente descrito, se podrá observar que formulación para solidificar sangre de origen animal ha sido Ideada para llevar a cabo la solidificación de sangre de origen animal con eficiencia, y será evidente para cualquier experto en la materia que las modalidades de la formulación para solidificar sangre de origen animal según se describió anteriormente, son únicamente ilustrativas más no limitativas de la presente invención, ya que son posibles numerosos cambios de consideración en sus detalles sin apartarse del alcance de la Invención.  In accordance with the above, it will be noted that formulation to solidify blood of animal origin has been devised to carry out solidification of blood of animal origin with efficiency, and it will be apparent to any person skilled in the art that the modalities of the formulation to solidify blood of animal origin as described above, they are only illustrative but not limiting of the present invention, since numerous changes of consideration in their details are possible without departing from the scope of the Invention.
Por lo tanto, la presente Invención no deberá considerarse como restringida excepto por lo que exija la técnica anterior y por el alcance de las reivindicaciones anexas.  Therefore, the present invention should not be considered as restricted except as required by the prior art and by the scope of the appended claims.

Claims

REIVINDICACIONES NOVEDAD DE LA INVENCIÓN NEWS CLAIMS OF THE INVENTION
1. Una formulación para solidificar sangre de origen animal que comprende al menos un agente gelificante; un agente acelerador de la coagulación; y un vehículo comestible. 1. A formulation for solidifying blood of animal origin comprising at least one gelling agent; a coagulation accelerating agent; and an edible vehicle.
2. La formulación para solidificar sangre de origen animal de conformidad con la reivindicación 1, caracterizada además porque el agente gelificante de la formulación es seleccionado de entre grenetina, goma guar y combinaciones de los mismos.  2. The formulation for solidifying blood of animal origin according to claim 1, further characterized in that the gelling agent of the formulation is selected from among grenetina, guar gum and combinations thereof.
3. La formulación para solidificar sangre de origen animal de conformidad con la reivindicación 1, caracterizada además porque el agente gelificante de la formulación está en una concentración de entre 1.5 y 14 % en peso.  3. The formulation for solidifying blood of animal origin according to claim 1, further characterized in that the gelling agent of the formulation is in a concentration of between 1.5 and 14% by weight.
4. La formulación para solidificar sangre de origen animal de conformidad con la reivindicación 1, caracterizada además porque el agente acelerador de la coagulación es cloruro de calcio.  4. The formulation for solidifying blood of animal origin according to claim 1, further characterized in that the coagulation accelerating agent is calcium chloride.
5. La formulación para solidificar sangre de origen animal de conformidad con la reivindicación 1, caracterizada además porque el agente acelerador de la coagulación está en una concentración de entre 1 y 5 % en peso.  5. The formulation for solidifying blood of animal origin according to claim 1, further characterized in that the coagulation accelerating agent is in a concentration of between 1 and 5% by weight.
6. La formulación para solidificar sangre de origen animal de conformidad con la reivindicación 1, caracterizada además porque el vehículo comestible se selecciona efe entre los grupos de alcoholes, dioles, ti oles, y combinaciones de los mismos.  6. The formulation for solidifying blood of animal origin according to claim 1, further characterized in that the edible vehicle is selected from among the groups of alcohols, diols, thiols, and combinations thereof.
7. La formulación para solidificar sangre de origen animal de conformidad con la reivindicación 1, caracterizada además porque el vehículo comestible se selecciona de entre glicerina, propilenglicol, etanol, y combinaciones de los mismos.  7. The formulation for solidifying blood of animal origin according to claim 1, further characterized in that the edible carrier is selected from glycerin, propylene glycol, ethanol, and combinations thereof.
8. La formulación para solidificar sangre de origen animal de conformidad con la reivindicación 1, caracterizada además porque el vehículo comestible está en una concentración de entre 9.6 y 27 % en peso.  8. The formulation for solidifying blood of animal origin according to claim 1, further characterized in that the edible vehicle is in a concentration between 9.6 and 27% by weight.
9. La formulación para solidificar sangre de origen animal de conformidad con la reivindicación l, caracterizada además porque la formulación contiene adicionalmente un conservador que no interviene con las reacciones de solidificación de la sangre.  9. The formulation for solidifying blood of animal origin according to claim 1, further characterized in that the formulation additionally contains a preservative that does not intervene with the solidification reactions of the blood.
10. La formulación para solidificar sangre de origen animal de conformidad con la reivindicación 9, caracterizada además porque el conservador se selecciona de entre benzoato de sodio y propionato de sodio.  10. The formulation for solidifying blood of animal origin according to claim 9, further characterized in that the preservative is selected from sodium benzoate and sodium propionate.
11. La formulación para solidificar sangre de origen animal de conformidad con la reivindicación 9, caracterizada además porque el conservador está en una concentración de entre 0.05 y 0.1% en peso. 11. The formulation for solidifying blood of animal origin according to claim 9, further characterized in that the preservative is in a concentration of between 0.05 and 0.1% by weight.
12. Un método para obtener una formulación para solidificar sangre de origen animal que comprende calentar un vehículo comestible; y añadir un agente gelificante y un agente acelerador de la coagulación al medio de suspensión comestible hasta obtener una solución homogénea. 12. A method for obtaining a formulation to solidify blood of animal origin comprising heating an edible vehicle; and add a gelling agent and a coagulation accelerating agent to the edible suspension medium until a homogeneous solution is obtained.
13. El método para obtener una formulación para solidificar sangre de origen animal de conformidad con la reivindicación 12, caracterizado además porque el vehículo comestible se selecciona de entre los grupos de alcoholes, dioles, boles, y combinaciones de los mismos.  13. The method for obtaining a formulation to solidify blood of animal origin according to claim 12, further characterized in that the edible vehicle is selected from the groups of alcohols, diols, bowls, and combinations thereof.
14. El método para obtener una formulación para solidificar sangre de origen animal de conformidad con la reivindicación 13, caracterizado además porque el vehículo comestible se selecciona de entre glicerina, propilenglico!, etanol, y combinaciones de los mismos.  14. The method for obtaining a formulation to solidify blood of animal origin according to claim 13, further characterized in that the edible vehicle is selected from glycerin, propylene glycol !, ethanol, and combinations thereof.
15. El método para obtener una formulación para solidificar sangre de origen animal de conformidad con la reivindicación 18, caracterizado además porque el vehículo comestible se callenta a una temperatura de entre 50 y 70°C.  15. The method for obtaining a formulation for solidifying blood of animal origin according to claim 18, further characterized in that the edible vehicle is stopped at a temperature between 50 and 70 ° C.
16. El método para obtener una formulación para solidificar sangre de origen animal de conformidad con la reivindicación 12, caracterizado además porque el agente gelificante es seleccionado de entre grenetina, goma guar, y combinaciones de los mismos.  16. The method for obtaining a formulation to solidify blood of animal origin according to claim 12, further characterized in that the gelling agent is selected from among grenetina, guar gum, and combinations thereof.
17. El método para obtener una formulación para solidificar sangre de origen animal de conformidad con la reivindicación 12, caracterizado además porque el agente acelerador de la coagulación es cloruro de calcio.  17. The method for obtaining a formulation to solidify blood of animal origin according to claim 12, further characterized in that the coagulation accelerating agent is calcium chloride.
18. El método para obtener una formulación para solidificar sangre de origen animal de conformidad con la reivindicación 12, caracterizado además porque el método comprende opcionalmente una etapa adicional en la que se agrega un conservador que no Intervenga con las reacciones de solidificación de la sangre.  18. The method for obtaining a formulation to solidify blood of animal origin according to claim 12, further characterized in that the method optionally comprises an additional step in which a preservative is added which does not intervene with the solidification reactions of the blood.
19. El método para obtener una formulación para solidificar sangre de origen animal de conformidad con la reivindicación 18, caracterizado además porque el conservador se selecciona de entre benzoato de sodio y propionato de sodio.  19. The method for obtaining a formulation to solidify blood of animal origin according to claim 18, further characterized in that the preservative is selected from sodium benzoate and sodium propionate.
20. Un método para solidificar sangre de origen animal que comprende mantener una formulación para solidificar sangre de origen animal a una temperatura de entre 50 y 70°C; añadir sangre de origen animal en estado líquido a la formulación; agitar la solución hasta obtener partículas sólidas de sangre; y separar dichas partículas de la solución.  20. A method for solidifying blood of animal origin comprising maintaining a formulation to solidify blood of animal origin at a temperature between 50 and 70 ° C; add blood of animal origin in liquid form to the formulation; stir the solution until solid particles of blood are obtained; and separating said particles from the solution.
21. Sangre sólida de origen animal, obtenida por el método para solidificar sangre de origen animal de conformidad con la reivindicación 20, caracterizada porque tiene una densidad de entre 1.080 y 1.12 g/mL  21. Solid blood of animal origin, obtained by the method for solidifying blood of animal origin according to claim 20, characterized in that it has a density of between 1,080 and 1.12 g / mL
22. Sangre sólida de origen animal de conformidad con la reivindicación 21, caracterizada porque tiene un módulo de elasticidad promedio de entre 40 y 133 KPa.  22. Solid blood of animal origin according to claim 21, characterized in that it has an average elastic modulus of between 40 and 133 KPa.
. .
23. Sangre sólida de origen animal de conformidad con la reivindicación 21, caracterizada porque tiene un valor cuadrático medio (RMS) de entre 1.2 y 2.35 KPa. 23. Solid blood of animal origin according to claim 21, characterized in that it has an average quadratic value (RMS) of between 1.2 and 2.35 KPa.
PCT/MX2018/000035 2018-03-09 2018-04-09 Formulation for solidifying blood of animal origin WO2019172740A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
MXMX/A/2018/002984 2018-03-09
MX2018002984A MX2018002984A (en) 2018-03-09 2018-03-09 Formulation for solidifying blood of animal origin.

Publications (1)

Publication Number Publication Date
WO2019172740A1 true WO2019172740A1 (en) 2019-09-12

Family

ID=67847415

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/MX2018/000035 WO2019172740A1 (en) 2018-03-09 2018-04-09 Formulation for solidifying blood of animal origin

Country Status (2)

Country Link
MX (1) MX2018002984A (en)
WO (1) WO2019172740A1 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4143168A (en) * 1975-12-08 1979-03-06 The Quaker Oats Company Shaped blood by-product and process
AU3892678A (en) * 1977-08-15 1980-02-21 Kliem Foods Pty. Ltd Production of food from blood
WO1991004672A1 (en) * 1989-09-29 1991-04-18 Andrew Kalinowski Treatment of animal blood
CN1335100A (en) * 2001-08-16 2002-02-13 徐大达 Dried blood and its production process
CN102125165A (en) * 2011-04-08 2011-07-20 汪前进 Production method of blood meal for feeding

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4143168A (en) * 1975-12-08 1979-03-06 The Quaker Oats Company Shaped blood by-product and process
AU3892678A (en) * 1977-08-15 1980-02-21 Kliem Foods Pty. Ltd Production of food from blood
WO1991004672A1 (en) * 1989-09-29 1991-04-18 Andrew Kalinowski Treatment of animal blood
CN1335100A (en) * 2001-08-16 2002-02-13 徐大达 Dried blood and its production process
CN102125165A (en) * 2011-04-08 2011-07-20 汪前进 Production method of blood meal for feeding

Also Published As

Publication number Publication date
MX2018002984A (en) 2019-09-10

Similar Documents

Publication Publication Date Title
JP7213205B2 (en) denatured collagen
CN107595809A (en) A kind of zeins nanometer embedding sustained release filler and preparation method thereof
CN101674839A (en) Process for producing osteocalcin-containing extract
JP2018187619A (en) emulsifier
RU1783984C (en) Process for producing an agent to compensate for deficiency of mineral salts in human organism
ES2307893T3 (en) METHOD FOR PREPARING A BLOOD PLASMA POWDER AND USES OF THE SAME.
KR101489916B1 (en) A method for extracting high purity collagen from animal byproducts
US9481718B2 (en) Extracting hirudin from leech in vivo
DE69414521T2 (en) METHOD FOR THE PRODUCTION OF IODIZED BIOPOLYMERS WITH DISINFECTING AND SCARF-PROMOTING EFFECT, AND THEREFORE PRODUCED IODATED BIOPOLYMERS
KR101433648B1 (en) Skin-beautifying agent
JP2006225270A (en) Tripeptide having sex hormone modification action, extract containing the same, eicosapentaenoic acid-bonded tripeptide, food preparation, cosmetic preparation and endometriosis treating agent containing the same
WO2019172740A1 (en) Formulation for solidifying blood of animal origin
JP7376964B2 (en) Method for producing animal tissue-derived living tissue, animal tissue-derived living material produced thereby, and three-dimensional printing method using the same
JPS63179818A (en) Bathing agent composition
JP2003313120A (en) Capsule form food composition
Tarigan et al. Extraction Of Functionally Active Collagen From Salmon Fish As Formulation Of Clay Mask
JPH06500496A (en) Microcapsules with walls of atelocollagen/polyholoside coagulated by divalent cations, methods for producing these microcapsules, and cosmetic, pharmaceutical or food compositions containing them
JP6324733B2 (en) Collagen triple helical structure stabilizer
KR970702288A (en) COMPLETELY DISSOLVED BONE TISSUE AND METHOD FOR PRODUCING THE SAME
NO156962B (en) PROCEDURE FOR PREPARATION AND PACKAGING OF FOODS INCLUDING PAINTING OF FISH PRODUCTS TO LIQUID AND Semi-LIQUID CONSISTENCY.
JP6117963B2 (en) Composition for promoting tissue regeneration, comprising polyamine as an active ingredient
JPS5849433A (en) Production of microcapsule
JP6846700B2 (en) Hyaluronan synthase gene expression promoter
KR102653697B1 (en) Composition for improving scalp and hair loss and manufacturing thereof
RU2740189C1 (en) Method for enrichment of therapeutic mud

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18908657

Country of ref document: EP

Kind code of ref document: A1